Unicycive
  • Home
  • Company
  • Therapeutic Focus
  • Pipeline
    • Oxylanthanum Carbonate (OLC)
    • UNI-494
  • Investors
  • Resources
  • Careers
  • Contact

News

Investors

Investors

  • Overview
  • News
  • Events & Presentations
    • IR Calendar
    • Presentations
  • Governance
    • Overview
    • Management Team
    • Board of Directors
    • Board Committees
    • Governance Documents
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Financial & Stock Info
    • Overview
    • Financial Results
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • Resources
    • Overview
    • Contacts
    • FAQ
    • Email Alerts
Dec 29, 2022 11:31am EST

Unicycive Announces Termination of “At-The-Market” Offering of Shares of Common Stock

Dec 28, 2022 8:30am EST

Unicycive Achieves Primary Endpoint in Pivotal Bioequivalence Study of Renazorb

Dec 22, 2022 7:00am EST

Unicycive Issued Notice of Acceptance to Initiate Phase 1 Study of UNI-494 Following Review of Clinical Trial Application by the Medicines and Healthcare Products Regulatory Agency in the United Kingdom

Nov 28, 2022 7:00am EST

Unicycive to Participate in Upcoming Investor Conferences

Nov 21, 2022 7:00am EST

Unicycive Reports Key Findings of UNI-494 Efficacy in Preclinical Animal Model of Geographic Atrophy

Nov 14, 2022 7:00am EST

Unicycive Announces Third Quarter Financial Results and Provides Business Update

Nov 10, 2022 7:00am EST

Unicycive Completes Enrollment of Pivotal Bioequivalence Study for RENAZORB™ (lanthanum dioxycarbonate), an Investigational Treatment for Hyperphosphatemia in Chronic Kidney Disease (CKD) Patients on Dialysis

Oct 26, 2022 8:04am EDT

Unicycive to Showcase Pipeline of Innovative Product Candidates at American Society of Nephrology’s Kidney Week 2022

Sep 29, 2022 7:00am EDT

Unicycive Therapeutics to Present at Roth Inaugural Healthcare Opportunities Conference

Sep 07, 2022 7:00am EDT

Unicycive Reports Key Findings of UNI-494 Efficacy in Preclinical Animal Model of Acute Kidney Injury (AKI)

  • arrow_back
  • 1…
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • arrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed

Legal Notices and Terms of Use
Privacy Policy
Ad and Cookie Policy
Contact Us >

Copyright © 2025 Unicycive

  • Twitter
  • LinkedIn
  • YouTube